NCT05731245View on ClinicalTrials.gov

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

October 12, 2024

Study Completion Date

October 12, 2026

Conditions
Pre-fibrotic Myelofibrosis
Interventions
DRUG

Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]

Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei, Taiwan, 100

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER